[go: up one dir, main page]

NO20042634L - 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser - Google Patents

3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser

Info

Publication number
NO20042634L
NO20042634L NO20042634A NO20042634A NO20042634L NO 20042634 L NO20042634 L NO 20042634L NO 20042634 A NO20042634 A NO 20042634A NO 20042634 A NO20042634 A NO 20042634A NO 20042634 L NO20042634 L NO 20042634L
Authority
NO
Norway
Prior art keywords
cyanoquinolines
egf
inhibitors
her2 kinases
her2
Prior art date
Application number
NO20042634A
Other languages
English (en)
Inventor
Allan Wissner
Hwei-Ru Tsou
Bernard Dean Johnson
Jr Middleton Brawner Floyd
Elsebe Geral Overbeek-Klumpers
Original Assignee
Wyeth Holdings Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Co filed Critical Wyeth Holdings Co
Publication of NO20042634L publication Critical patent/NO20042634L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20042634A 2001-11-27 2004-06-23 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser NO20042634L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33356801P 2001-11-27 2001-11-27
PCT/US2002/037918 WO2003050090A1 (en) 2001-11-27 2002-11-26 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Publications (1)

Publication Number Publication Date
NO20042634L true NO20042634L (no) 2004-06-23

Family

ID=23303345

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042634A NO20042634L (no) 2001-11-27 2004-06-23 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser

Country Status (24)

Country Link
US (1) US6821988B2 (no)
EP (1) EP1448531B1 (no)
JP (1) JP2005514384A (no)
KR (1) KR20050044599A (no)
CN (1) CN1659145A (no)
AR (1) AR037438A1 (no)
AT (1) ATE370123T1 (no)
AU (1) AU2002359489B2 (no)
BR (1) BR0214485A (no)
CA (1) CA2467573A1 (no)
CO (1) CO5580828A2 (no)
DE (1) DE60221886D1 (no)
EC (1) ECSP045122A (no)
HU (1) HUP0402228A2 (no)
IL (1) IL161921A0 (no)
MX (1) MXPA04004969A (no)
NO (1) NO20042634L (no)
NZ (1) NZ533118A (no)
PL (1) PL370137A1 (no)
RU (1) RU2309150C2 (no)
TW (1) TW200300348A (no)
UA (1) UA77469C2 (no)
WO (1) WO2003050090A1 (no)
ZA (1) ZA200405025B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
JP2007501238A (ja) * 2003-08-01 2007-01-25 ワイス・ホールディングズ・コーポレイション 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
BR0318503A (pt) * 2003-09-15 2006-09-12 Wyeth Corp quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
PL2392565T3 (pl) * 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
JP2008509923A (ja) 2004-08-13 2008-04-03 ジェネンテック・インコーポレーテッド Ａｔｐ利用酵素のチアゾールベースのインヒビター
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
BRPI0606839B8 (pt) 2005-02-03 2021-12-14 Massachusetts Gen Hospital Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7624279B2 (en) * 2005-06-29 2009-11-24 Lenovo Singapore Pte. Ltd. System and method for secure O.S. boot from password-protected HDD
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
KR101467723B1 (ko) 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
CA2654515C (en) * 2006-06-13 2014-04-01 Wyeth Substituted 3-cyanopyridines as protein kinase inhibitors
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
SG191676A1 (en) 2008-06-17 2013-07-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
ITMI20082336A1 (it) * 2008-12-29 2010-06-30 Univ Parma Composti inibitori irreversibili di egfr con attivita' antiproliferativa
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
ES2564797T3 (es) 2009-08-19 2016-03-29 Eisai R&D Management Co., Ltd. Composición farmacéutica con contenido en un derivado de quinolina
WO2011056741A2 (en) 2009-11-09 2011-05-12 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
BR112012031340B1 (pt) * 2010-06-09 2021-09-14 Tianjin Hemay Bio-Tech Co., Ltd Derivados de cianoquinolina, composição farmacêutica compreendendo os mesmos, e seu uso
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
WO2012027537A1 (en) * 2010-08-26 2012-03-01 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
CN103304494B (zh) * 2013-06-20 2015-05-27 河北大学 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
US10774068B2 (en) * 2015-06-25 2020-09-15 The Scripps Research Institute Composition and methods for inhibiting mammalian sterile 20-like kinase 1
ES2887426T3 (es) 2015-08-20 2021-12-22 Eisai R&D Man Co Ltd Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
US20190016703A1 (en) * 2015-12-30 2019-01-17 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
SI3658552T1 (sl) 2017-07-28 2023-11-30 Yuhan Corporation Postopek za pripravo N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il )amino)-4-metoksi-2-morfolinofenil)akrilamida z reagiranjem ustreznega amina s 3-halo-propionil kloridom
CN110452232A (zh) * 2019-09-17 2019-11-15 北京振东光明药物研究院有限公司 阿法替尼杂质化合物及其制备方法与应用
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
WO2024187321A1 (zh) * 2023-03-10 2024-09-19 甫康（上海）健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9707495A (pt) * 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
EP1950201A1 (en) 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
KR100705142B1 (ko) * 1998-09-29 2007-04-06 와이어쓰 홀딩스 코포레이션 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CN1262541C (zh) 1999-12-29 2006-07-05 惠氏公司 三环蛋白激酶抑制剂
US7067532B2 (en) * 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents

Also Published As

Publication number Publication date
CA2467573A1 (en) 2003-06-19
AR037438A1 (es) 2004-11-10
PL370137A1 (en) 2005-05-16
NZ533118A (en) 2006-07-28
KR20050044599A (ko) 2005-05-12
CN1659145A (zh) 2005-08-24
UA77469C2 (en) 2006-12-15
EP1448531A1 (en) 2004-08-25
MXPA04004969A (es) 2004-08-11
TW200300348A (en) 2003-06-01
AU2002359489A1 (en) 2003-06-23
CO5580828A2 (es) 2005-11-30
ECSP045122A (es) 2004-07-23
US20030149056A1 (en) 2003-08-07
RU2004119414A (ru) 2006-02-27
US6821988B2 (en) 2004-11-23
HUP0402228A2 (hu) 2005-02-28
WO2003050090A1 (en) 2003-06-19
RU2309150C2 (ru) 2007-10-27
DE60221886D1 (de) 2007-09-27
ATE370123T1 (de) 2007-09-15
BR0214485A (pt) 2004-09-14
IL161921A0 (en) 2005-11-20
ZA200405025B (en) 2006-12-27
AU2002359489B2 (en) 2008-10-30
EP1448531B1 (en) 2007-08-15
JP2005514384A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
NO20042634L (no) 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser
NO20050636L (no) Inhibitorer av tyrosinkinaser
NO20052888D0 (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
IS6968A (is) Nýir týrósínkínasa tálmar
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1370554T3 (da) 3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer
NO20045220L (no) Heterocykliske inhibitorer for kinaser
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
NO20053242D0 (no) 4-substituerte benzimidazoler og deres anvendelse som inhibitorer av gastrisk sekresjon.
IL161516A0 (en) Benzimidazoles useful as protein kinase inhibitors
AU2002357882A8 (en) Small-molecule inhibitors of interleukin-2
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20042244L (no) Fenylsubstituerte triazoler og deres anvendelse som selektive inhibitorer av AKL5-kinease
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
EP1651599A4 (en) TYROSINE KINASE INHIBITORS
EP1496897A4 (en) Tyrosine kinase inhibitor
EE200300491A (et) 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena
MXPA03009257A (es) Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application